Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... DEARBORN, Mich. , July 7, 2015  SME,s ... for its third-annual "30 Under 30" issue, celebrating young ... in manufacturing. The July issue of ... young manufacturing professionals and students for their accomplishments. Among ... with the U.S. Air Force on optimizing the topology ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... uBiome, ... of up to $100,000 of microbiome sampling kits and full 16S laboratory analysis. The ... and well-being. The winner will also have access to their own dashboard, enabling them ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... membership driven community in the biometrical area. What began as a conference for ... global community for various functions in the biometrical area. Statistical Programmers, Data Managers ...
(Date:7/7/2015)... FL (PRWEB) , ... July 07, 2015 , ... ... ActiGraph’s CentrePoint Study Admin system was developed to solve many of ... and analysis, particularly within studies that involve multiple clinical sites and/or remote data ...
Breaking Biology Technology:SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 2SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 3SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 4SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 5uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3PhUSE Delighted to Welcome Member Number 5.000 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3
... Mich., Sept. 26 The Beaumont Technology,Usability ... helping smaller and,start-up medical technology companies speed ... FDA regulators will join BTUC product-usability and,human-factors ... effective methods,for meeting FDA risk assessment requirements. ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today announced ... of,the inaugural companies in the new NASDAQ(R) NeuroInsights(R) ... an index designed to track,the performance of selected ... three major U.S. stock exchanges. The NASDAQ NeuroInsights,Neurotech ...
... 26 CuraGen Corporation,(Nasdaq: CRGN ), ... today that Ronit Simantov, M.D., has joined ... Dr. Simantov is a seasoned and accomplished ... and academic positions. In her,previous position at ...
Cached Biology Technology:Beaumont Technology Usability Center To Offer Training For Medical Technology Companies 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 3CuraGen Appoints Clinical Oncologist as VP of Medical Development 2CuraGen Appoints Clinical Oncologist as VP of Medical Development 3CuraGen Appoints Clinical Oncologist as VP of Medical Development 4
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... 2013) The world,s leading conservation organizations have joined together ... eastern lowland gorilla ( Gorilla beringei graueri ). Found ... Democratic Republic of Congo (DRC), Grauer,s gorilla is not only ... largest primate in the world. With their entire range ...
... advance toward overcoming a major barrier to tapping the ... medicine in developing new and more effective modern drugs. ... Information and Modeling . Andreas Bender and ... modern medicine. In the world,s largest international clinical trial, ...
... World, the first international conference examining the critical link ... the University of Pennsylvania from Wednesday, March 13, through ... Penn Institute for Urban Research (Penn IUR), in partnership ... Steering Committee representing nine schools and six centers, is ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3Penn conference tackles complex relationship between urbanization and food 2
...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
Rabbit polyclonal to QKI...
... M-PER Mammalian Protein Extraction Reagent ... lysis solution that means no ... no sonication! With M-PER Reagent, ... five minutes at room temperature, ...
Biology Products: